Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tetravalent Influenza Virus Split Vaccine (MDCK) in Individuals Aged 3 Years and Above
ChiCTR2300076221Phase 3Not yet recruiting
- Sponsor
- Shandong Provincial Center for Disease Prevention and Control
- Start
- Sep 2023
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of tetravalent influenza vaccine in influenza (6 arms), sponsored by Shandong Provincial Center for Disease Prevention and Control. Planned start Sep 2023; status: not yet recruiting.
02
Drugs
tetravalent influenza vaccine
03
Conditions
influenza
Beyond the preview
Go deeper on ChiCTR2300076221.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2300076221.